Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection
Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection
This is a multi-center prospective study that aims to investigate the clinical and
 immunologic impact of SARS-CoV-2 infection in pregnant women and neonates. The goal is to
 recruit 200 SARS-CoV-2 infected pregnant women starting at 24 weeks of gestation in a
 neonatal network of 45.000 birth a year. Clinical data will be collected from women and
 neonates. Upper airways samples will be obtained from both for bio-markers investigation.
 Finally, maternal and umbilical cord serum and human milk will be obtained for antibody
 assessment.
COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, has led to an unprecedented
 global pandemic affecting persons of all ages. Pregnant women are in a physiologic
 immunosuppressed situation and have a greater risk and severity of respiratory infection.
 However, considerable uncertainty exists regarding the potential for vertical transmission
 (prenatal/congenital or perinatal) of SARS-CoV-2 from infected pregnant women to their
 newborns and its potential clinical consequences.

 This study attempts to provide evidence-based guidelines for managing antenatal, intrapartum,
 and neonatal care around COVID-19 require an understanding of whether the virus can be
 transmitted transplacentally; a determination of which maternal body fluids may be
 infectious; trasnplacental and human milk antibody transfer and data of adequate statistical
 power that describe which maternal, intrapartum, and neonatal factors influence perinatal
 transmission.
Inclusion Criteria:

 -  Pregnant women hospitalized presenting with:

 1. Fever with one or more respiratory symptoms (cough, odinophagia, respiratory
 difficulty)

 2. Diagnoses of pneumonia with no other explainable cause.

 Exclusion Criteria:

 -  None